Afstyla
Payments companies reported to CMS as associated with Afstyla. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Afstyla, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Afstyla
These are the largest totals companies reported as associated with Afstyla. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Shawn Jobe | Lansing, MI | Pediatric Hematology-Oncology | $2,938.16 |
| Cindy Leissinger | New Orleans, LA | Hematology & Oncology | $572.87 |
| Janet William | Cerritos, CA | Nurse Practitioner | $241.58 |
| Debbie Thomas | Riverside, CA | Nurse Practitioner | $200.11 |
| Nuruddin Jooma | Clearwater, FL | Medical Oncology | $192.63 |
| Samir Kubba | San Bernardino, CA | Hematology & Oncology | $179.21 |
| Xinyu Nan | Orange, CA | Hematology & Oncology | $165.29 |
| Rajiv Malik | San Bernardino, CA | Hematology & Oncology | $160.54 |
| Nejra Tabakovic | Clearwater, FL | Physician Assistant | $157.01 |
| Anas Raowas | Fountain Valley, CA | Hematology & Oncology | $152.23 |
Prescribed Afstyla?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.